Every 424B that EVOGENE LTD. (EVGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EVGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVGN filings page.
EVGN is amending its existing at-the-market equity program with A.G.P./Alliance Global Partners to increase the maximum aggregate offering price of its ordinary shares from $2,926,500 to $3,288,113 under its Form F-3 shelf registration.
The ordinary shares, par value 0.2 NIS, may be sold from time to time in transactions deemed “at the market offerings” under Rule 415, with A.G.P. acting as sales agent on a best efforts basis for a 3.0% commission on gross sales. To date, EVGN has sold approximately $1,753,025.13 of ordinary shares under the Sales Agreement. The aggregate market value of public float was about $9,864,339.62 as of July 17, 2026, and the remaining capacity to sell securities under General Instruction I.B.5. of Form F-3 was $1,535,088.08.
Evogene Ltd. is offering up to $2,926,500 of its ordinary shares in an at-the-market (ATM) program under a Sales Agreement with A.G.P./Alliance Global Partners dated June 11, 2026. Sales may occur from time to time on Nasdaq or otherwise at prevailing market prices, with A.G.P. paid a 3.0% commission.
The prospectus supplement states the company’s public float was approximately $8,779,546 (based on $0.85 per share and 10,328,878 shares held by non-affiliates). The offering table shows 12,104,457 ordinary shares outstanding prior to the offering as of June 3, 2026 and illustrates an illustrative post-offering outstanding count of up to 17,006,467 shares assuming sale of 4,902,010 shares at $0.597 per share (the last reported sale on June 9, 2026).
Evogene Ltd. registers 2,446,707 ordinary shares for resale by a selling shareholder via Prospectus Supplement No. 1. This supplement adds the company's GAAP Q1 2026 financial statements and updates the prospectus dated March 26, 2026.
The consolidated balance sheet shows $8.5M cash and cash equivalents as of March 31, 2026 and 10,412,764 ordinary shares issued and outstanding as of March 31, 2026. The three‑month loss was $(5,896) thousand. The resale is by a selling shareholder; issuer proceeds are not received from these resales.